tag medicare 
Fierce Healthcare
JUNE 9, 2023
Emerging Alzheimer’s disease medications come with high price tags, but researchers with the University of Chicago calculate that in the long run, it’s much less costly to cover these therapies for | Emerging Alzheimer’s medications come with high price tags, but researchers with the University of Chicago calculate that in the long run, it’s much less (..)
STAT
JANUARY 30, 2024
In response to concerns over multimillion-dollar price tags for new gene therapies for sickle cell disease, the U.S. To cope, the Centers for Medicare and Medicaid Services will pursue so-called outcomes-based agreements. Two therapies recently approved by health regulators cost $2.2 million and $3.1
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
MARCH 10, 2023
By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products. But neither factor has much effect, the studies concluded.
STAT
MARCH 10, 2023
Enjoy, and see you soon … By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products , STAT explains. Two But be safe.
STAT
AUGUST 2, 2023
Medicare and Medicaid patients will make up 92% of the market for the drug, called Leqembi. Besides the $26,500 annual price tag, treatment could cost U.S. The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S.
pharmaphorum
OCTOBER 21, 2021
Aduhelm is currently under review by the Center for Medicare and Medicaid Services (CMS), which isn’t due to deliver recommendations on reimbursement until next year – which Vounatsos said was delaying treatment for patients who might benefit from the drug.
PharmD Live
DECEMBER 21, 2021
A 3.75% cut in the 2022 Medicare conversion factor, which calculates reimbursement for procedures under fee-for-service, is mandated under a budget neutrality provision and comes after a pay bump from Congress that expires in 2022. Fee-for-service reimbursement falls as quality performance pay increases. Aduhelm earns FDA approval.
Expert insights. Personalized for you.
145 
Let's personalize your content